GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
GlaxoSmithKline said on April 6 the company’s consumer arm stopped shipments of supplements and vitamins to Russia as a result of Moscow’s invasion of Ukraine and would prioritize the supply of over-the-counter medicines for basic needs.
Novartis will launch a new phase three study to expand the use of Zolgensma – the world’s most expensive one-time therapy at $2.1 million per patient treatment – after the U.S. regulator lifted its restrictions.
MacroGenics Inc. announced a partnership with Eversana to commercialize margetuximab in the United States, if approved.
How pharma can help deliver better experiences to health care providers today and following COVID-19Artificial Intelligence, Business, Coronavirus Disease 2019 (COVID-19), Data, Digital, Email, HCPs, Health Technology, Healthcare Marketers, Healthcare Providers, Marketing communications, Pharma, Sales & Marketing
Pharmaceutical companies are no strangers to digital technology, either in the science that creates their products or in the business of bringing them to the people who prescribe them. As the use of digital-first experiences intensifies and the pharmaceutical industry is forced to evolve, companies will need to lean on their data and technologies in their engagement efforts to deliver elevated human experiences.
“Put the patient first.” It’s every pharma marketer’s favorite buzz-phrase in 2020. And why not? Patients are our real customers; they use and (hopefully) benefit from our products, and their wants and needs drive the success or failure of everything we do.
The state of California sued Juul Labs Inc., alleging the e-cigarette maker engaged in a “systematic” and “wildly successful” campaign to attract teenagers to the San Francisco company’s nicotine devices.
Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.